None listed
Conditions
Interventions
None listed
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adult men and women over 19 years of age 2) Patients with EGFR mutation-positive advanced/metastatic non-small cell lung cancer who have been treated with afatinib or gefitinib for more than 6 months as first-line treatment 3) Patients with confirmed T790M mutation positive in tumor tissue or blood samples after failure of afatinib or gefitinib treatment as first-line treatment 4) Patients who received osimertinib as a second-line treatment after confirming acquired resistance T790M mutation 5) Patients with T790M allele frequency results obtained from tumor tissue or blood samples after afatinib or gefitinib treatment as the first treatment
Exclusion criteria
Exclusion criteria: 1) Patients unable to review medical records 2) Patients with brain metastases Patients with brain metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint for this study is the allelic frequency of T790M mutation in two Cohorts with tumor tissue or blood samples after first-line EGFR-TKI disease progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Objective response rate (ORR) and time on treatment (TOT) according to the T790M allelic frequency and second-/first-line EGFR-TKI treatments. • Additional experimental endpoint on prognostic significance according to the T790M allelic frequency. | — |
Countries
Korea, Republic of
Contacts
Public Contactwonjun ji
Asan Medical Center
Outcome results
None listed